|
JPS4934761B1
(enExample)
|
1969-03-10 |
1974-09-18 |
|
|
|
US5080898A
(en)
|
1982-05-12 |
1992-01-14 |
The University Hospital |
Enzymatically active toxin coupled to a cell-specific ligand
|
|
US5668255A
(en)
|
1984-06-07 |
1997-09-16 |
Seragen, Inc. |
Hybrid molecules having translocation region and cell-binding region
|
|
US6022950A
(en)
|
1984-06-07 |
2000-02-08 |
Seragen, Inc. |
Hybrid molecules having translocation region and cell-binding region
|
|
US5091178A
(en)
|
1986-02-21 |
1992-02-25 |
Oncogen |
Tumor therapy with biologically active anti-tumor antibodies
|
|
US7838216B1
(en)
|
1986-03-05 |
2010-11-23 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Human gene related to but distinct from EGF receptor gene
|
|
US6893625B1
(en)
|
1986-10-27 |
2005-05-17 |
Royalty Pharma Finance Trust |
Chimeric antibody with specificity to human B cell surface antigen
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
US5506126A
(en)
|
1988-02-25 |
1996-04-09 |
The General Hospital Corporation |
Rapid immunoselection cloning method
|
|
US4861579A
(en)
|
1988-03-17 |
1989-08-29 |
American Cyanamid Company |
Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
|
|
US5135736A
(en)
|
1988-08-15 |
1992-08-04 |
Neorx Corporation |
Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
|
|
CA2055441C
(en)
|
1989-05-19 |
2003-01-07 |
Robert M. Hudziak |
Her2 extracellular domain
|
|
AU657087B2
(en)
|
1989-12-22 |
1995-03-02 |
Seragen Incorporated |
Hybrid molecules having translocation region and cell-binding region
|
|
US5578482A
(en)
|
1990-05-25 |
1996-11-26 |
Georgetown University |
Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
|
|
US5635384A
(en)
|
1990-06-11 |
1997-06-03 |
Dowelanco |
Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using
|
|
US5834229A
(en)
|
1991-05-24 |
1998-11-10 |
Genentech, Inc. |
Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
|
|
IL101943A0
(en)
|
1991-05-24 |
1992-12-30 |
Genentech Inc |
Structure,production and use of heregulin
|
|
EP0940468A1
(en)
|
1991-06-14 |
1999-09-08 |
Genentech, Inc. |
Humanized antibody variable domain
|
|
US5621083A
(en)
|
1991-11-04 |
1997-04-15 |
Xoma Corporation |
Immunotoxins comprising ribosome-inactivating proteins
|
|
US6146850A
(en)
|
1991-11-04 |
2000-11-14 |
Xoma Corporation |
Proteins encoding gelonin sequences
|
|
US5552144A
(en)
*
|
1992-01-22 |
1996-09-03 |
Microcarb, Inc. |
Immunogenic shiga-like toxin II variant mutants
|
|
WO1993021319A1
(en)
|
1992-04-08 |
1993-10-28 |
Cetus Oncology Corporation |
HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
|
|
CA2131003A1
(en)
|
1992-05-26 |
1993-12-09 |
Raymond G. Goodwin |
Novel cytokine that binds cd30
|
|
JPH08504172A
(ja)
|
1992-06-30 |
1996-05-07 |
オンコロジクス，インコーポレイティド |
抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
|
|
EP1005870B1
(en)
|
1992-11-13 |
2009-01-21 |
Biogen Idec Inc. |
Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
US5869445A
(en)
|
1993-03-17 |
1999-02-09 |
University Of Washington |
Methods for eliciting or enhancing reactivity to HER-2/neu protein
|
|
CA2162689C
(en)
|
1993-05-12 |
2000-07-18 |
Xoma Corporation |
Immunotoxins comprising gelonin and an antibody
|
|
US5484892A
(en)
|
1993-05-21 |
1996-01-16 |
Dana-Farber Cancer Institute, Inc. |
Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
|
|
US5417972A
(en)
|
1993-08-02 |
1995-05-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
|
|
US5595721A
(en)
|
1993-09-16 |
1997-01-21 |
Coulter Pharmaceutical, Inc. |
Radioimmunotherapy of lymphoma using anti-CD20
|
|
US20020164788A1
(en)
|
1994-12-02 |
2002-11-07 |
The Wellcome Foundation Limited |
Humanized antibodies to CD38
|
|
GB9424449D0
(en)
|
1994-12-02 |
1995-01-18 |
Wellcome Found |
Antibodies
|
|
ATE186745T1
(de)
|
1995-01-18 |
1999-12-15 |
Roche Diagnostics Gmbh |
Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern
|
|
WO1996030043A1
(en)
|
1995-03-24 |
1996-10-03 |
Ophidian Pharmaceuticals |
Treatment for verotoxin-producing escherichia coli
|
|
US5667786A
(en)
|
1995-06-07 |
1997-09-16 |
Novavax, Inc. |
Method for treating tumors with a toxin
|
|
ATE483733T1
(de)
|
1995-06-14 |
2010-10-15 |
Univ California |
Hochaffine humane antikörper gegen tumorantigene
|
|
AU6777596A
(en)
|
1995-08-25 |
1997-03-19 |
Dana-Farber Cancer Institute |
Treatment of human prostate disease with beta-lapachone derivatives
|
|
US5783186A
(en)
|
1995-12-05 |
1998-07-21 |
Amgen Inc. |
Antibody-induced apoptosis
|
|
US5858682A
(en)
|
1996-08-02 |
1999-01-12 |
Pharmingen |
E2A/pbx1 fusion protein specific monoclonal antibodies
|
|
CZ295838B6
(cs)
|
1996-09-09 |
2005-11-16 |
Zealand Pharma A/S |
Způsob výroby peptidů
|
|
WO1998011229A2
(en)
|
1996-09-10 |
1998-03-19 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof
|
|
US5770380A
(en)
|
1996-09-13 |
1998-06-23 |
University Of Pittsburgh |
Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
|
|
CA2269204C
(en)
|
1996-10-18 |
2012-01-24 |
Genentech, Inc. |
Anti-erbb2 antibodies
|
|
ATE383430T1
(de)
|
1997-03-20 |
2008-01-15 |
Us Gov Health & Human Serv |
Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
|
|
US6306393B1
(en)
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
|
AU6919798A
(en)
|
1997-04-24 |
1998-11-13 |
Crisplant A/S |
A conveyor unit for use in a closed loop conveyor system and a conveyor system
|
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
|
ES2244066T3
(es)
|
1997-06-24 |
2005-12-01 |
Genentech, Inc. |
Procedimiento y composiciones de glicoproteinas galactosiladas.
|
|
US6368596B1
(en)
|
1997-07-08 |
2002-04-09 |
Board Of Regents, The University Of Texas System |
Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
|
|
FR2766193B1
(fr)
*
|
1997-07-18 |
2001-09-14 |
Inst Curie |
Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
|
|
EP1028751B1
(en)
|
1997-10-31 |
2008-12-31 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
|
CA2222993A1
(en)
|
1998-02-04 |
1999-08-04 |
The Ontario Cancer Institute |
A method for using a ribosome-inactivating protein complex as a structural template and a molecular search engine in the design, construction and screening of combinatorial protein libraries
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
AU770718B2
(en)
|
1998-06-05 |
2004-02-26 |
Mayo Foundation For Medical Education And Research |
Use of genetically engineered antibodies to CD38 to treat multiple myeloma
|
|
US7157418B1
(en)
*
|
1998-07-22 |
2007-01-02 |
Osprey Pharmaceuticals, Ltd. |
Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
|
|
CA2335105C
(en)
|
1998-07-22 |
2010-05-11 |
Osprey Pharmaceuticals Limited |
Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
|
|
US6770456B1
(en)
|
1998-07-29 |
2004-08-03 |
Ludwig Institute For Cancer Research |
Endogenous retrovirus tumor associated nucleic acids and antigens
|
|
KR101023367B1
(ko)
|
1998-08-11 |
2011-03-18 |
바이오겐 아이덱 인크. |
Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제
|
|
WO2000020579A1
(en)
|
1998-10-02 |
2000-04-13 |
Mcmaster University |
Spliced form of erbb-2/neu oncogene
|
|
US6224866B1
(en)
|
1998-10-07 |
2001-05-01 |
Biocrystal Ltd. |
Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
|
|
KR20010103655A
(ko)
|
1998-11-09 |
2001-11-23 |
케네쓰 제이. 울코트 |
키메라 항-ｃｄ２０항체를 이용한 순환성 종양세포와관련된 혈액학적 악성종양의 치료법
|
|
BR9915149A
(pt)
|
1998-11-09 |
2001-08-07 |
Idec Pharma Corp |
Tratamento com anticorpo anti-cd20 quimérico de pacientes recebendo transplantes de bmt ou de pbsc
|
|
KR101077001B1
(ko)
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
US7625859B1
(en)
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
|
US6897044B1
(en)
|
1999-01-28 |
2005-05-24 |
Biogen Idec, Inc. |
Production of tetravalent antibodies
|
|
EP1161455B1
(en)
*
|
1999-03-16 |
2008-09-03 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
A novel chimeric protein for prevention and treatment of hiv infection
|
|
HK1043312B
(en)
|
1999-05-07 |
2006-07-28 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
|
|
US7527787B2
(en)
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
|
US7144991B2
(en)
|
1999-06-07 |
2006-12-05 |
Aletheon Pharmaceuticals, Inc. |
Streptavidin expressed gene fusions and methods of use thereof
|
|
EP1194167B1
(en)
|
1999-06-09 |
2009-08-19 |
Immunomedics, Inc. |
Immunotherapy of autoimmune disorders using antibodies which target b-cells
|
|
ITMI991299A1
(it)
|
1999-06-11 |
2000-12-11 |
Consiglio Nazionale Ricerche |
Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
|
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
DE19930748C2
(de)
|
1999-07-02 |
2001-05-17 |
Infineon Technologies Ag |
Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
|
|
EP1189931B1
(en)
|
1999-07-02 |
2006-06-21 |
Genentech, Inc. |
Peptide compounds that bind her2
|
|
HUP0202238A3
(en)
|
1999-07-12 |
2004-05-28 |
Idec Pharmaceuticals Inc San D |
Blocking immune response to a foreign antigen using an antagonist which binds to cd20
|
|
US6451284B1
(en)
|
1999-08-11 |
2002-09-17 |
Idec Pharmaceuticals Corporation |
Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
|
|
CN101259270A
(zh)
|
1999-08-11 |
2008-09-10 |
拜奥根Idec公司 |
用抗cd20抗体治疗累及骨髓的非霍奇金淋巴瘤患者
|
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
|
WO2001013945A1
(en)
|
1999-08-23 |
2001-03-01 |
Biocrystal Ltd. |
Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
|
|
US6492498B1
(en)
|
1999-11-15 |
2002-12-10 |
Regents Of The University Of Minnesota |
Multimeric immunotoxins
|
|
US20010031485A1
(en)
|
2000-03-22 |
2001-10-18 |
Sibtech, Inc. |
Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments
|
|
US7267973B2
(en)
|
2000-03-22 |
2007-09-11 |
Sibtech, Inc. |
Nucleic acids encoding recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor
|
|
AU2001247737A1
(en)
|
2000-03-24 |
2001-10-08 |
Chiron Corporation |
Methods of therapy for non-hodgkin's lymphoma using a combination of an antibodyto cd20 and interleuking-2
|
|
ES2637801T3
(es)
|
2000-04-11 |
2017-10-17 |
Genentech, Inc. |
Anticuerpos multivalentes y usos de los mismos
|
|
EP1286692A4
(en)
|
2000-04-25 |
2004-11-17 |
Idec Pharma Corp |
INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR THE TREATMENT OF LYMPHOMAS OF THE CENTRAL NERVOUS SYSTEM
|
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
|
EP1299128A2
(en)
|
2000-06-20 |
2003-04-09 |
Idec Pharmaceuticals Corporation |
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
|
EP1174440A1
(en)
|
2000-07-19 |
2002-01-23 |
U-BISys B.V. |
A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
|
|
US20020127247A1
(en)
|
2000-11-17 |
2002-09-12 |
Allergen Sales, Inc. |
Modified clostridial neurotoxins with altered biological persistence
|
|
US7090843B1
(en)
|
2000-11-28 |
2006-08-15 |
Seattle Genetics, Inc. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
US20040018194A1
(en)
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
DE10063048A1
(de)
|
2000-12-18 |
2002-07-11 |
Deutsches Krebsforsch |
Einzelketten-Antikörper mit verbesserter Stabilität
|
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
WO2002096948A2
(en)
|
2001-01-29 |
2002-12-05 |
Idec Pharmaceuticals Corporation |
Engineered tetravalent antibodies and methods of use
|
|
EP1373321A2
(en)
|
2001-01-29 |
2004-01-02 |
Idec Pharmaceuticals Corporation |
Modified antibodies and methods of use
|
|
JP2005500018A
(ja)
|
2001-04-02 |
2005-01-06 |
アイデック ファーマスーティカルズ コーポレイション |
ＧｎＴＩＩＩと同時発現する組換え抗体
|
|
WO2003061694A1
(en)
|
2001-05-10 |
2003-07-31 |
Seattle Genetics, Inc. |
Immunosuppression of the humoral immune response by anti-cd20 antibodies
|
|
WO2002102312A2
(en)
|
2001-06-14 |
2002-12-27 |
Intermune, Inc. |
Combination therapy of gamma-interferon and b cell specific antibodies
|
|
US7321026B2
(en)
|
2001-06-27 |
2008-01-22 |
Skytech Technology Limited |
Framework-patched immunoglobulins
|
|
US7446185B2
(en)
|
2001-07-18 |
2008-11-04 |
The Regents Of The University Of California |
Her2/neu target antigen and use of same to stimulate an immune response
|
|
ATE468348T1
(de)
|
2001-09-26 |
2010-06-15 |
Government Of The Us Secretary |
Mutierte anti-cd22-antikörper mit erhöhter affinität zu cd22-exprimierenden leukämiezellen
|
|
CN1638800A
(zh)
|
2002-01-09 |
2005-07-13 |
米德列斯公司 |
抗cd30的人类单克隆抗体
|
|
AU2003208097A1
(en)
|
2002-02-04 |
2003-09-02 |
Hideo Yoshida |
Anticancer agents using vero toxin variants
|
|
WO2003072736A2
(en)
|
2002-02-21 |
2003-09-04 |
Duke University |
Reagents and treatment methods for autoimmune diseases
|
|
JP4597528B2
(ja)
*
|
2002-02-26 |
2010-12-15 |
ジェネンコー・インターナショナル・インク |
免疫原性が減少したズブチリシン・カールスバーグタンパク質
|
|
ATE477276T1
(de)
|
2002-03-01 |
2010-08-15 |
Immunomedics Inc |
Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
|
|
US20040248151A1
(en)
|
2002-04-05 |
2004-12-09 |
Ventana Medical Systems, Inc. |
Method for predicting the response to HER2-directed therapy
|
|
CA2481515C
(en)
|
2002-04-10 |
2013-10-01 |
Genentech, Inc. |
Anti-her2 antibody variants
|
|
US7449480B2
(en)
|
2002-05-14 |
2008-11-11 |
Baylor College Of Medicine |
Small molecule inhibitors of HER2 expression
|
|
US7019017B2
(en)
|
2002-05-14 |
2006-03-28 |
Baylor College Of Medicine |
Small molecule inhibitors of HER2 expression
|
|
WO2004032828A2
(en)
|
2002-07-31 |
2004-04-22 |
Seattle Genetics, Inc. |
Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
|
|
ES2347241T3
(es)
|
2002-12-16 |
2010-10-27 |
Genentech, Inc. |
Variantes de inmunoglobulina y sus utilizaciones.
|
|
AU2003303374A1
(en)
|
2002-12-20 |
2004-07-22 |
The Johns Hopkins University |
Treatment of metastatic cancer with the b-subunit of shiga toxin
|
|
JP2006525787A
(ja)
|
2003-01-03 |
2006-11-16 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
アカゲザルＨＥＲ２／ｎｅｕ、これをコードするヌクレオチド及びその使用
|
|
WO2005000901A2
(en)
|
2003-05-09 |
2005-01-06 |
Duke University |
Cd20-specific antibodies and methods of employing same
|
|
AR044388A1
(es)
|
2003-05-20 |
2005-09-07 |
Applied Molecular Evolution |
Moleculas de union a cd20
|
|
WO2005000902A1
(en)
|
2003-06-30 |
2005-01-06 |
Mu-Hyeon Choe |
The dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same
|
|
ATE416190T1
(de)
|
2003-07-04 |
2008-12-15 |
Affibody Ab |
Polypeptide mit bindungsaffinität für her2
|
|
EP2216342B1
(en)
|
2003-07-31 |
2015-04-22 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
EP1660010B1
(en)
|
2003-08-01 |
2013-07-24 |
A & G Pharmaceutical, Inc. |
Compositions and methods for restoring sensitivity to treatment with her2 antagonists
|
|
US8147832B2
(en)
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
|
ATE468356T1
(de)
|
2003-11-25 |
2010-06-15 |
Us Gov Health & Human Serv |
Mutierte anti-cd22-antikörper und immunkonjugate
|
|
EP1687016A4
(en)
|
2003-11-25 |
2009-07-29 |
Anjin Corp |
GENETIC VARIANT OF DIPHTHERIC TOXIN
|
|
AU2005235811B2
(en)
|
2004-02-06 |
2011-11-03 |
Morphosys Ag |
Anti-CD38 human antibodies and uses therefor
|
|
NZ548990A
(en)
|
2004-02-06 |
2009-06-26 |
Morphosys Ag |
Anti-CD38 human antibodies and uses therefor
|
|
ES2386338T3
(es)
|
2004-03-26 |
2012-08-17 |
Molecular Templates, Inc. |
Colección de mutantes de toxinas y métodos para su uso
|
|
KR20110050567A
(ko)
|
2004-07-22 |
2011-05-13 |
제넨테크, 인크. |
Ｈｅｒ２ 항체 조성물
|
|
EP3312196B1
(en)
|
2005-03-23 |
2019-07-17 |
Genmab A/S |
Antibodies against cd38 for treatment of multiple myeloma
|
|
ATE517183T1
(de)
|
2005-03-31 |
2011-08-15 |
Biomedics Inc |
Monoklonaler antikörper gegen cd20
|
|
WO2007040653A2
(en)
|
2005-05-16 |
2007-04-12 |
The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services National Institutes Of Health |
Anti-cd30 antibodies that bind to intact cd30 but not soluble cd30
|
|
US7771955B2
(en)
|
2005-06-09 |
2010-08-10 |
University Of Maryland |
Affinity membrane for capture of a target biomolecule and formation thereof by site-directed immobilization of a capture biomolecule
|
|
EA019344B1
(ru)
|
2005-07-01 |
2014-03-31 |
МЕДАРЕКС, Эл.Эл.Си. |
Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
|
|
FI20055417A0
(fi)
|
2005-07-20 |
2005-07-20 |
Glykos Finland Oy |
Syöpäpesifiset glykaanit ja niiden käyttö
|
|
CA2616386A1
(en)
|
2005-07-25 |
2007-02-01 |
Trubion Pharmaceuticals Inc. |
Single dose use of cd20-specific binding molecules
|
|
CA2664549A1
(en)
|
2005-09-26 |
2007-03-29 |
University Health Network |
Library from toxin mutants, and methods of using same
|
|
JP2009520468A
(ja)
|
2005-12-23 |
2009-05-28 |
ヴィヴェンティア バイオテック インコーポレーティッド |
融合タンパク質ライブラリーの作製法およびスクリーニング法、ならびにそれらの使用
|
|
ES2532985T3
(es)
|
2006-02-16 |
2015-04-06 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Proteínas quiméricas de toxoide de Shiga
|
|
US7373982B2
(en)
|
2006-03-21 |
2008-05-20 |
Halliburton Energy Services, Inc. |
Cements for use across formations containing gas hydrates
|
|
WO2008073160A2
(en)
*
|
2006-08-17 |
2008-06-19 |
The Trustees Of Columbia University In The City Of New York |
Methods for converting or inducing protective immunity
|
|
WO2008025020A2
(en)
|
2006-08-25 |
2008-02-28 |
Seattle Genetics, Inc. |
Cd30 binding agents and uses thereof
|
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
BRPI0717902A2
(pt)
|
2006-12-01 |
2013-10-29 |
Medarex Inc |
"anticorpo monoclonal humano isolado, composição, conjugado anticorpo-molécula parceria, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para prepar um anticorpo anti-cd22, método para inibir o desenvolvimento de uma célula tumoral que expressa cd22 e método para tratar uma doença inflamatória ou autoimuneem um indivíduo"
|
|
CN101622352A
(zh)
*
|
2006-12-29 |
2010-01-06 |
美国奥斯普瑞医药公司 |
选择和产生修饰的毒素、含有修饰的毒素的缀合物的方法及其应用
|
|
BRPI0720647A2
(pt)
|
2006-12-29 |
2014-01-14 |
Osprey Pharmaceuticals Usa Inc |
Processos de seleção e produção de toxinas modificadas, conjugados contendo toxinas modificadas e usos dos mesmos
|
|
EP2173373B1
(en)
|
2007-06-06 |
2020-04-15 |
Sarepta Therapeutics, Inc. |
Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
|
|
WO2009014835A2
(en)
|
2007-06-21 |
2009-01-29 |
Angelica Therapeutics, Inc. |
Modified toxins
|
|
US7887801B2
(en)
|
2007-07-13 |
2011-02-15 |
Topotarget Germany Ag |
Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
|
|
US7879984B2
(en)
|
2007-07-31 |
2011-02-01 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to human CD20 and method of using thereof
|
|
WO2009017823A2
(en)
|
2007-08-01 |
2009-02-05 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health |
A fold-back diabody diphtheria toxin immunotoxin and methods of use
|
|
CA2698357C
(en)
|
2007-09-04 |
2017-06-06 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
|
|
US20110263825A1
(en)
|
2007-09-06 |
2011-10-27 |
Osaka University |
Anti-cd20 monoclonal antibodies
|
|
EP2207793A2
(en)
|
2007-10-08 |
2010-07-21 |
Rutgers, The State University |
Nontoxic shiga-like toxin mutant compositions and methods
|
|
AU2008321026B2
(en)
|
2007-11-13 |
2014-01-16 |
The Scripps Research Institute |
Production of cytotoxic antibody-toxin fusion in eukaryotic algae
|
|
CN101970490A
(zh)
|
2007-11-27 |
2011-02-09 |
埃博灵克斯股份有限公司 |
针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
|
|
EP2245754B1
(en)
|
2007-12-17 |
2016-03-02 |
Unwired Planet International Limited |
Multi-antenna receiver interference cancellation method and apparatus
|
|
EP2072525A1
(en)
|
2007-12-21 |
2009-06-24 |
Affibody AB |
New polypeptides having affinity for HER2
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
EP2268297A4
(en)
|
2008-02-29 |
2011-11-16 |
Angelica Therapeutics Inc |
MODIFIED TOXINS
|
|
ES2342646B1
(es)
|
2008-06-02 |
2011-04-26 |
Institut De Recerca Hospital Universitari Vall Hebron |
Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
|
|
US7919273B2
(en)
|
2008-07-21 |
2011-04-05 |
Immunomedics, Inc. |
Structural variants of antibodies for improved therapeutic characteristics
|
|
AU2009293640A1
(en)
|
2008-09-22 |
2010-03-25 |
Calmune Corporation |
Methods and vectors for display of 2G12 -derived domain exchanged antibodies
|
|
BRPI0919377A2
(pt)
|
2008-09-26 |
2016-09-27 |
Dana Farber Cancer Inst Inc |
anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
|
|
NZ593926A
(en)
|
2009-01-23 |
2013-03-28 |
Jackson H M Found Military Med |
Methods and compositions based on shiga toxin type 2 protein
|
|
AU2010240569A1
(en)
|
2009-04-20 |
2011-10-20 |
Pfizer Inc. |
Control of protein glycosylation and compositions and methods relating thereto
|
|
EP2456470A1
(en)
|
2009-07-22 |
2012-05-30 |
Cenix Bioscience GmbH |
Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
|
|
CN102575542B
(zh)
|
2009-08-14 |
2014-09-10 |
尤尼弗瑞克斯I有限责任公司 |
用于排气处理装置的安装垫
|
|
EP2496604B1
(en)
|
2009-11-06 |
2017-08-23 |
IDEXX Laboratories, Inc. |
Canine anti-cd20 antibodies
|
|
US9616120B2
(en)
|
2010-03-04 |
2017-04-11 |
Vet Therapeutics, Inc. |
Monoclonal antibodies directed to CD20
|
|
EP2371864A1
(en)
|
2010-03-23 |
2011-10-05 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies for treatment of cancer
|
|
CA2796180A1
(en)
|
2010-04-15 |
2011-10-20 |
Alper Biotech, Llc |
Monoclonal antibodies against her2 antigens, and uses therefor
|
|
CA3051311A1
(en)
*
|
2010-05-27 |
2011-12-01 |
Genmab A/S |
Monoclonal antibodies against her2
|
|
GB201013989D0
(en)
|
2010-08-20 |
2010-10-06 |
Univ Southampton |
Biological materials and methods of using the same
|
|
CN101948546B
(zh)
*
|
2010-09-25 |
2012-11-07 |
中国人民解放军军事医学科学院微生物流行病研究所 |
融合蛋白SAmB及其编码基因与应用
|
|
US20120141505A1
(en)
|
2010-11-01 |
2012-06-07 |
Fatih M. Uckun |
Cd19-ligand and use
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
PL219845B1
(pl)
|
2011-01-05 |
2015-07-31 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
Przeciwnowotworowe białko fuzyjne
|
|
EP2667898A1
(en)
|
2011-01-26 |
2013-12-04 |
Cenix Bioscience GmbH |
Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
|
|
ES2700514T3
(es)
|
2011-02-01 |
2019-02-18 |
Genmab As |
Anticuerpos humanos y conjugados de anticuerpo-fármaco contra CD74
|
|
US8895006B2
(en)
|
2011-03-04 |
2014-11-25 |
Rutgers, The State University Of New Jersey |
Ricin ribosome binding protein compositions and methods of use thereof
|
|
BR112013028537A2
(pt)
|
2011-05-06 |
2017-01-17 |
Us Gov Health & Human Serv |
imunotoxina recombinante que visa a mesotelina
|
|
EP2717912A4
(en)
|
2011-06-08 |
2015-08-05 |
Univ California |
ANTI-CD22-ANTIGEN-BINDING MOLECULES FOR THE TREATMENT OF LUNG CANCER AND PROSTATE CANCER
|
|
EA026924B1
(ru)
|
2011-08-01 |
2017-05-31 |
Дженентек, Инк. |
Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
|
|
PL397167A1
(pl)
*
|
2011-11-28 |
2013-06-10 |
Adamed Spólka Z Ograniczona Odpowiedzialnoscia |
Przeciwnowotworowe bialko fuzyjne
|
|
US20150044210A1
(en)
|
2012-02-23 |
2015-02-12 |
President And Fellows Of Harvard College |
Modified microbial toxin receptor for delivering agents into cells
|
|
ES2649991T3
(es)
|
2012-11-19 |
2018-01-16 |
Baliopharm Ag |
Anticuerpo biespecífico recombinante que se une a CD20 y CD95
|
|
EP2740493A1
(en)
*
|
2012-12-05 |
2014-06-11 |
Institut Curie |
Conjugates of the B-subunit of Shiga toxin for anticancer therapies
|
|
EP2970487B1
(en)
|
2013-03-12 |
2020-03-11 |
Molecular Templates, Inc. |
Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
|
|
EP2778173A1
(en)
*
|
2013-03-15 |
2014-09-17 |
Laboratoire Français du Fractionnement et des Biotechnologies |
Antibody directed against anthrax toxins and its uses
|
|
JP6090020B2
(ja)
|
2013-07-10 |
2017-03-08 |
富士ゼロックス株式会社 |
画像形成システム
|
|
US10808035B2
(en)
|
2013-08-26 |
2020-10-20 |
Markus Chmielewski |
Anti CD30 chimeric antigen receptor and its use
|
|
GB2519786A
(en)
|
2013-10-30 |
2015-05-06 |
Sergej Michailovic Kiprijanov |
Multivalent antigen-binding protein molecules
|
|
US20150118251A1
(en)
|
2013-10-31 |
2015-04-30 |
Sanofi |
Specific anti-cd38 antibodies for treating human cancers
|
|
KR20160113158A
(ko)
*
|
2014-01-27 |
2016-09-28 |
몰레큘러 템플레이츠, 인코퍼레이션. |
폴리펩티드를 전달하는 mhc 클래스 i 항원결정기
|
|
US20210138076A2
(en)
|
2014-01-27 |
2021-05-13 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
|
|
US20160177284A1
(en)
|
2014-01-27 |
2016-06-23 |
Molecular Templates, Inc. |
Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions
|
|
US10421958B2
(en)
|
2014-02-05 |
2019-09-24 |
Molecular Templates, Inc. |
Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
|
|
EP3872090A1
(en)
|
2014-03-11 |
2021-09-01 |
Molecular Templates, Inc. |
Proteins comprising amino-terminal proximal shiga toxin a subunit effector regions and cell-targeting immunoglobulin-type binding regions
|
|
WO2015138435A1
(en)
|
2014-03-11 |
2015-09-17 |
Molecular Templates, Inc. |
Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
|
|
US11142584B2
(en)
|
2014-03-11 |
2021-10-12 |
Molecular Templates, Inc. |
CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
|
|
WO2015136947A1
(en)
|
2014-03-14 |
2015-09-17 |
Raqualia Pharma Inc. |
Azaspiro derivatives as trpm8 antagonists
|
|
US10815469B2
(en)
|
2014-06-11 |
2020-10-27 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising protease-cleavage resistant, Shiga toxin A subunit effector polypeptides and carboxy-terminal moieties
|
|
WO2015191883A1
(en)
|
2014-06-12 |
2015-12-17 |
Dophen Biomedical |
Homogenous antibody drug conjugates via enzymatic methods
|
|
EP3157958B1
(en)
|
2014-06-18 |
2020-05-06 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Car-expressing nk-92 cells as cell therapeutic agents
|
|
CN105713087B
(zh)
|
2014-11-12 |
2020-05-08 |
北京康乐卫士生物技术股份有限公司 |
人乳头瘤病毒58型单克隆抗体及其应用
|
|
JP6444486B2
(ja)
|
2015-02-05 |
2018-12-26 |
モレキュラー テンプレーツ, インク.Molecular Templates, Inc. |
志賀毒素ａサブユニットエフェクター領域を含む多価ｃｄ２０結合分子及びそれらの強化組成物
|
|
CN115093479A
(zh)
|
2015-03-04 |
2022-09-23 |
Igm生物科学股份有限公司 |
Cd20结合分子及其用途
|
|
JP6771492B2
(ja)
|
2015-05-30 |
2020-10-21 |
モレキュラー テンプレーツ, インク.Molecular Templates, Inc. |
脱免疫化された志賀毒素ａサブユニット足場及びそれを含む細胞標的化分子
|
|
MX2018001208A
(es)
|
2015-07-26 |
2018-03-26 |
Molecular Templates Inc |
Moleculas con direccion a las celulas que comprenden efectores de la subunidad a de la toxina shiga y epitopos de celulas-t cd8+.
|
|
ES2973870T3
(es)
|
2016-03-29 |
2024-06-24 |
Univ Texas |
Anticuerpos de función doble específicos para PD-L1 glucosilado y métodos de uso de los mismos
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
RU2770590C2
(ru)
|
2016-10-30 |
2022-04-18 |
Шанхай Хенлиус Байотек, Инк. |
Антитела против pd-l1 и их варианты
|
|
JP7075134B2
(ja)
|
2016-12-07 |
2022-05-25 |
モレキュラー テンプレーツ，インク． |
部位特異的コンジュゲーションのための志賀毒素ａサブユニットエフェクターポリペプチド、志賀毒素エフェクター足場、及び細胞標的化分子
|
|
US11597914B2
(en)
|
2016-12-26 |
2023-03-07 |
Dankook University Cheonan Campus Industry Academic Cooperation Foundation |
IgG type monoclonal antibodies specifically binding to odontoblast surface
|
|
KR102590672B1
(ko)
|
2017-01-25 |
2023-10-18 |
몰레큘러 템플레이츠, 인코퍼레이션. |
탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
|
|
WO2018159615A1
(en)
|
2017-02-28 |
2018-09-07 |
Chugai Seiyaku Kabushiki Kaisha |
Protein purification with protein l
|
|
WO2018162749A1
(en)
|
2017-03-09 |
2018-09-13 |
Genmab A/S |
Antibodies against pd-l1
|
|
JP7159151B2
(ja)
|
2017-09-25 |
2022-10-24 |
Jsr株式会社 |
イムノグロブリン結合タンパク質、及びそれを用いたアフィニティー担体
|
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
|
WO2020154475A1
(en)
|
2019-01-23 |
2020-07-30 |
Molecular Templates, Inc. |
Proteins comprising modified immunoglobulin variable light chains
|
|
CN114423793A
(zh)
|
2019-09-18 |
2022-04-29 |
分子模板公司 |
包含志贺菌毒素a亚基支架的pd-l1结合分子
|